OZEM vs. SBIO ETF Comparison
Comparison of Roundhill GLP-1 & Weight Loss ETF (OZEM) to ALPS Medical Breakthroughs ETF (SBIO)
OZEM
Roundhill GLP-1 & Weight Loss ETF
OZEM Description
OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
Grade (RS Rating)
Last Trade
$27.32
Average Daily Volume
31,803
14
SBIO
ALPS Medical Breakthroughs ETF
SBIO Description
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.Grade (RS Rating)
Last Trade
$38.26
Average Daily Volume
6,572
83
Performance
Period | OZEM | SBIO |
---|---|---|
30 Days | -0.27% | 1.91% |
60 Days | -5.30% | 2.27% |
90 Days | 3.02% | 7.65% |
12 Months | 52.91% |
OZEM Underweight 81 Positions Relative to SBIO
Symbol | Grade | Weight | |
---|---|---|---|
RNA | C | -3.38% | |
KRYS | C | -3.33% | |
CRNX | B | -3.04% | |
ACLX | B | -3.02% | |
IMVT | F | -2.93% | |
ALKS | F | -2.88% | |
DNLI | C | -2.39% | |
MRUS | C | -2.38% | |
FOLD | B | -2.27% | |
ZLAB | B | -2.11% | |
PTCT | B | -2.05% | |
XENE | C | -2.03% | |
EWTX | B | -2.03% | |
VRNA | A | -1.83% | |
PTGX | B | -1.77% | |
CGON | F | -1.67% | |
AGIO | B | -1.65% | |
IDYA | F | -1.61% | |
ACAD | F | -1.57% | |
GERN | C | -1.55% | |
VERA | A | -1.5% | |
KROS | A | -1.41% | |
VCEL | D | -1.35% | |
LBPH | A | -1.34% | |
AKRO | A | -1.3% | |
MIRM | B | -1.25% | |
GLPG | F | -1.25% | |
ARVN | C | -1.22% | |
CLDX | F | -1.21% | |
MNKD | A | -1.14% | |
BCRX | A | -1.1% | |
SNDX | F | -1.07% | |
IMCR | F | -1.06% | |
RCUS | F | -1.04% | |
NTLA | F | -1.03% | |
TARS | A | -0.97% | |
VRDN | B | -0.93% | |
SPRY | B | -0.92% | |
IRON | D | -0.9% | |
KURA | F | -0.89% | |
COGT | B | -0.89% | |
XNCR | A | -0.87% | |
DAWN | A | -0.85% | |
PHVS | A | -0.77% | |
APLT | A | -0.71% | |
AUPH | A | -0.65% | |
ANAB | F | -0.59% | |
PRTA | F | -0.58% | |
LQDA | C | -0.58% | |
PLRX | A | -0.56% | |
ETNB | D | -0.54% | |
REPL | B | -0.53% | |
ERAS | C | -0.48% | |
ANNX | B | -0.47% | |
OLMA | F | -0.46% | |
MLYS | B | -0.44% | |
YMAB | A | -0.43% | |
IRWD | F | -0.4% | |
CELC | D | -0.4% | |
ALLO | D | -0.38% | |
SVRA | D | -0.37% | |
FLGT | C | -0.37% | |
URGN | F | -0.35% | |
ARCT | F | -0.35% | |
AURA | B | -0.34% | |
FULC | F | -0.34% | |
ALEC | D | -0.3% | |
CMPS | F | -0.29% | |
AVXL | A | -0.29% | |
TBPH | C | -0.28% | |
FDMT | F | -0.27% | |
GHRS | D | -0.25% | |
ALDX | D | -0.21% | |
ACIU | F | -0.2% | |
INZY | F | -0.19% | |
STRO | D | -0.19% | |
ITOS | F | -0.19% | |
ENTA | D | -0.17% | |
VNDA | D | -0.17% | |
ZNTL | D | -0.15% | |
HLVX | C | -0.06% |
OZEM: Top Represented Industries & Keywords
SBIO: Top Represented Industries & Keywords